鶹ý

Few Stick With Ozempic; Pfizer Making Daily GLP-1; Once-Weekly Insulin Turned Down

— News and commentary from the endocrinology world

MedpageToday
Endo Break over a computer rendering of a man with illustrated body organs.

Only 25% of (Ozempic, Wegovy) for weight loss were still on it 2 years later, according to an analysis of U.S. pharmacy claims data by Prime Therapeutics and Magellan Rx Management.

A study in older patients with type 2 diabetes found no clear increased risk of suicidal ideation with use of . (Annals of Internal Medicine)

Pfizer said it's developing a weight loss pill.

In postmenopausal women with osteoporosis, romosozumab (Evenity) yielded after 12 months compared with teriparatide and with lower discontinuation rates. (Journal of Clinical Endocrinology & Metabolism)

Novo Nordisk said the its once-weekly insulin for diabetes after a negative advisory committee review.

Meanwhile, the company faces scrutiny on Capitol Hill after from the U.S. market. (Reuters)

Authors of a viewpoint said Switzerland has an overall higher per-capita uptake of GLP-1 agents for weight loss. The drugs are reimbursed there, but the country has negotiated lower prices and applies stricter prerequisites for administration and monitoring. The authors argue that such a system may make GLP-1 drugs more affordable and reduce off-label use and shortages.

Members of an Australian religious group are on trial after being accused of killing an 8-year-old girl with diabetes by and offering prayer instead. (BBC)

People exposed to brighter night light and light patterns that may disrupt circadian rhythms had a . (Lancet Regional Health Europe)

Could a hormone released by the hold promise as an osteoporosis treatment? (Science)

Meet : another "forever chemical" in drinking water that may be more prevalent than previously thought. (Washington Post)

  • author['full_name']

    Kristen Monaco is a senior staff writer, focusing on endocrinology, psychiatry, and nephrology news. Based out of the New York City office, she’s worked at the company since 2015.